Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of the MEK Inhibitor Trametinib With the AKT Inhibitor GSK2141795 in BRAF Wild-type Melanoma

NCT01941927 is registered in ClinicalTrials.gov with Adil Daud as lead sponsor.

NCT NCT01941927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01941927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of the MEK Inhibitor Trametinib With the AKT Inhibitor GSK2141795 in BRAF Wild-type Melanoma
Lead sponsor
Adil Daud
Phase
Phase 2
Overall status
Completed
Start date
September 10, 2013
Completion date
May 3, 2017
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma